Dermatology Clinical Trials | Clinical Trials GPS

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 12/31/1969

2169

from 98109

Alpharetta, GA

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 12/31/1969

988

from 98109

Fountain Valley, CA

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 12/31/1969

1939

from 98109

Louisville, KY

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 12/31/1969

Dermatology / Plastic Surgery, Hematology, Immunology / Infectious Diseases, Oncology, Reproductive Clinical Trial

1970

from 98109

Nashville, TN

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Status: Enrolling, Phase
Updated: 12/31/1969

Saint Alphonsus Medical Center-Baker City

290

from 98109

Baker City, OR

Dermatology / Plastic Surgery, Hematology, Immunology / Infectious Diseases, Oncology, Reproductive Clinical Trial

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Status: Enrolling, Phase
Updated: 12/31/1969

OhioHealth Mansfield Hospital

2005

from 98109

Mansfield, OH

Dermatology / Plastic Surgery, Hematology, Immunology / Infectious Diseases, Oncology, Reproductive Clinical Trial

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Status: Enrolling, Phase
Updated: 12/31/1969

Delbert Day Cancer Institute at PCRMC

1674

from 98109

Rolla, MO

Dermatology / Plastic Surgery, Hematology, Immunology / Infectious Diseases, Oncology, Reproductive Clinical Trial

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Status: Enrolling, Phase
Updated: 12/31/1969

Geisinger Medical Oncology-Selinsgrove

2267

from 98109

Selinsgrove, PA

Keratoconus Clinical Trial

Keratoconus Detection by Ultrasound

Status: Enrolling, Phase
Updated: 12/31/1969

London Vision Clinic

4787

from 98109

London,

Human Papillomavirus Infection Clinical Trial

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Status: Enrolling, Phase III
Updated: 4/18/2014

Human Papillomavirus Infection Clinical Trial

1366

from 98109

Omaha, NE

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Status: Enrolling, Phase III
Updated: 4/18/2014

1066

from 98109

Spring Valley, CA

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Status: Enrolling, Phase II
Updated: 1/21/2016

1184

from 98109

Albuquerque, NM

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Status: Enrolling, Phase II
Updated: 1/21/2016

2482

from 98109

Johnston, RI

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Status: Enrolling, Phase II
Updated: 1/21/2016

626

from 98109

Sacramento, CA

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Status: Enrolling, Phase II
Updated: 1/21/2016

1929

from 98109

Warren, MI

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Status: Enrolling, Phase II
Updated: 1/21/2016

2692

from 98109

West Palm Beach, FL

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Status: Enrolling, Phase II
Updated: 2/29/2016

2113

from 98109

Knoxville, TN

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Status: Enrolling, Phase II
Updated: 2/29/2016

2358

from 98109

Raleigh, NC

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Status: Enrolling, Phase II
Updated: 2/29/2016

229

from 98109

Spokane, WA

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Status: Enrolling, Phase II
Updated: 2/29/2016

1720

from 98109

St. Louis, MO

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Status: Enrolling, Phase II
Updated: 2/29/2016

2458

from 98109

Stony Brook, NY

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

Status: Enrolling, Phase III
Updated: 7/6/2016

Glenmark Investigational Site 53

1967

from 98109

Cincinnati, OH

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 2/28/2017

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

2291

from 98109

High Point, NC

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Status: Enrolling, Phase II
Updated: 2/28/2017

2400

from 98109

New York, NY

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1184

from 98109

Albuquerque, NM

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2169

from 98109

Alpharetta, GA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1889

from 98109

Bellaire, TX

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2389

from 98109

Berlin, NJ

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2341

from 98109

Bethlehem, PA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2708

from 98109

Boca Raton, FL

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2424

from 98109

Charleston, SC

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2449

from 98109

Jacksonville, FL

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

962

from 98109

Los Angeles, CA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2255

from 98109

Macon, GA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2415

from 98109

Newport News, VA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

984

from 98109

Orange, CA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2544

from 98109

Orlando, FL

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1116

from 98109

Phoenix, AZ

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

147

from 98109

Portland, OR

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1633

from 98109

Rogers, AR

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1720

from 98109

Saint Louis, MO

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2172

from 98109

Sandy Springs, GA

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2527

from 98109

Tampa, FL

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

1922

from 98109

Troy, MI

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

2422

from 98109

Trumbull, CT

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 2/7/2017

Dermatology / Plastic Surgery, Neurology Clinical Trial

1911

from 98109

Webster, TX

Dermatology / Plastic Surgery Clinical Trial

Maintaining Lower Levels of Care Through Automated Perineal Hygiene

Status: Enrolling
Updated: 12/31/1969

The Village at Marymount

2027

from 98109

Garfield Heights, OH

Brentuximab Vedotin for Systemic Sclerosis

Status: Enrolling, Phase I, II
Updated: 12/31/1969

University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics

1891

from 98109

Houston, TX

Dermatology / Plastic Surgery, Neurology Clinical Trial

Brentuximab Vedotin for Systemic Sclerosis

Status: Enrolling, Phase I, II
Updated: 12/31/1969

University of Pittsburgh Medical Center: Division of Rheumatology and Clinical

2134

from 98109

Pittsburgh, PA

Rady Children's Hospital - San Diego/University of California, San Diego

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Status: Enrolling, Phase IV
Updated: 12/31/1969

1060

from 98109

San Diego, CA

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Status: Enrolling, Phase IV
Updated: 12/31/1969

Dermatology Specialists of Spokane

229

from 98109

Spokane, WA

Rady Children's Hospital - San Diego/University of California, San Diego

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

1060

from 98109

San Diego, CA

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Pace Dermatology Associates

from 98109

Tacoma, WA

Dermatology / Plastic Surgery Clinical Trial

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Status: Enrolling, Phase II
Updated: 12/31/1969

Apex Dermatology

1025

from 98109

Denver, CO

Dermatology / Plastic Surgery Clinical Trial

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Status: Enrolling, Phase II
Updated: 12/31/1969

AboutSkin Dermatology and DermSurgery

1027

from 98109

Greenwood Village, CO

Atopic Dermatitis (AD) Clinical Trial

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

Status: Enrolling, Phase IV
Updated: 12/31/1969

Brigham and Women's Hospital

2484

from 98109

Foxboro, MA

Urticaria Clinical Trial

Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)

Status: Enrolling, Phase II
Updated: 12/31/1969

Allergy & Asthma Immunology Associates

1116

from 98109

Scottsdale, AZ

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Renaissance Research Medical Group, INC

2616

from 98109

Cape Coral, FL

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Innovate Research, LLC

1653

from 98109

Fort Worth, TX

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Forefront Dermatology, S.C.

1939

from 98109

Louisville, KY

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Qualmedica Research

1894

from 98109

Owensboro, KY

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

M3-Wake Research, Inc.

2357

from 98109

Raleigh, NC

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

MediSearch Clinical Trials

1469

from 98109

Saint Joseph, MO

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

San Luis Dermatology & Laser Clinic, Inc.

856

from 98109

San Luis Obispo, CA

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Kirk Barber Research

440

from 98109

Calgary,

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Miami Dermatology & Laser Research

2731

from 98109

Miami, FL

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

University of Utah MidValley Dematology

707

from 98109

Murray, UT

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Status: Enrolling, Phase III
Updated: 12/31/1969

Site 117

2836

from 98109

Belize City,

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Status: Enrolling, Phase III
Updated: 12/31/1969

2720

from 98109

Miramar, FL

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Status: Enrolling, Phase III
Updated: 12/31/1969

2527

from 98109

Tampa, FL

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

440

from 98109

Calgary,

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

Regeneron Investigational Site 1

1662

from 98109

Fort Worth, TX

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

1870

from 98109

Indianapolis, IN

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

2252

from 98109

Macon, GA

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

704

from 98109

Palo Alto, CA

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

1383

from 98109

Plymouth, MN

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

979

from 98109

Rolling Hills Estates, CA

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to

Status: Enrolling, Phase III
Updated: 12/31/1969

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

635

from 98109

Santa Rosa, CA

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 204

697

from 98109

Fremont, CA

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 209

1389

from 98109

Fridley, MN

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 371

1467

from 98109

Saint Joseph, MO

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 514

926

from 98109

Santa Ana, CA

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Status: Enrolling, Phase II
Updated: 12/31/1969

Dermatologists of Greater Colombus

2011

from 98109

Bexley, OH

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Status: Enrolling, Phase II
Updated: 12/31/1969

Revival Research

2722

from 98109

Doral, FL

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Status: Enrolling, Phase II
Updated: 12/31/1969

Innovate Research, LLC

1653

from 98109

Fort Worth, TX

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Status: Enrolling, Phase II
Updated: 12/31/1969

ActivMed Practices & Research, Inc.

2477

from 98109

Portsmouth, NH

DMT310-001 Topical in the Treatment of Acne Vulgaris

Status: Enrolling, Phase II
Updated: 12/31/1969

Dermata Investigational Site

1770

from 98109

Austin, TX

DMT310-001 Topical in the Treatment of Acne Vulgaris

Status: Enrolling, Phase II
Updated: 12/31/1969

Dermata Investigational Site

2183

from 98109

High Point, NC

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

DMT310-001 Topical in the Treatment of Acne Vulgaris

Status: Enrolling, Phase II
Updated: 12/31/1969

Dermata Investigational Site

1065

from 98109

San Diego, CA

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 506

1902

from 98109

Ann Arbor, MI

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 365

1770

from 98109

Austin, TX

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 221

1767

from 98109

Bryant, AR

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 524

1998

from 98109

Dublin, OH

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 525

2329

from 98109

Glenn Dale, MD

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 511

2110

from 98109

Knoxville, TN

Dermatology / Plastic Surgery, Otolaryngology Clinical Trial

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Status: Enrolling, Phase III
Updated: 12/31/1969

Study Site 227

1367

from 98109

Omaha, NE

Lichen Sclerosus Clinical Trial

Biomarkers of Lichen Sclerosus

Status: Enrolling, Phase
Updated: 12/31/1969

The Centers for Vulvovaginal Disorders

2321

from 98109

Washington DC,

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis

Status: Enrolling, Phase III
Updated: 12/31/1969

Vanda Investigational Site

1970

from 98109

Nashville, TN